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40 WORD SUMMARY 
Reflecting upon the historical Pasteur–Bechamp debates on the role of the ‘microbe’ versus the 
‘host internal milieu’ in disease causation, we describe the case for parallel investments into a 
range of adjunct host-directed therapies for improving TB treatment outcomes. 
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Abstract (150 words) 
Tuberculosis (TB) remains a global emergency causing an estimated 1.5 million deaths annually. For 
several decades the major focus of TB treatment has been on antibiotic development targeting 
Mycobacterium tuberculosis (M.tb). The lengthy TB treatment duration and poor treatment 
outcomes associated with multi-drug resistant TB (MDR-TB) are of major concern. The sparse new 
TB drug pipeline and widespread emergence of MDR-TB signal an urgent need for more innovative 
interventions to improve treatment outcomes. Building on the historical Pasteur-Bechamp debates 
on the role of the ‘microbe’ versus the ‘host internal milieu’ in disease causation, we make the case 
for parallel investments into host-directed therapies (HDTs). A range of potential HDTs are now 
available which require evaluation in randomized controlled clinical trials as adjunct therapies for 
shortening the duration of TB therapy and improving treatment outcomes for drug-susceptible TB 
and MDR-TB. Funder initiatives that may enable further research into HDTs are described. 
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Tuberculosis (TB) remains a global emergency causing an estimated 1.5 million deaths annually.1 For 
several decades the major focus of TB treatment has been on antibiotic development targeting 
Mycobacterium tuberculosis (M.tb). The lengthy TB treatment duration and poor treatment 
outcomes associated with Multi-drug resistant TB (MDR-TB), and co-morbidity of TB with HIV are 
also of major concern. In May 2014, the World Health Assembly adopted the World Health 
Organization (WHO) post-2015 global TB strategy,  which aims to reduce global TB incidence by 90% 
before 2035.2  Given the special challenges of TB in countries with low levels of the disease, WHO in 
collaboration with the European Respiratory Society, and with experts from low-incidence countries 
has developed an eight-point framework adapted from the post-2015 global TB strategy to target 
pre-elimination and, ultimately, elimination. 3    
Every year, progress being made towards achieving global TB control targets is reflected upon by the 
global TB community on World TB Day March 24th.4-6 The TB community have been re-assured by 
WHO Annual Global TB reports over the past decade showing a steady decline of TB rates 
worldwide. Further optimism for achieving the Millennium Development Goal’s TB control targets 
came from a number of potentially important developments, including: introduction of a new rapid 
diagnostic test, the GeneXpert MTB/RIF assay7 and its widespread rollout; new drugs entering phase 
II and III trials, including PA-8248; fast-track approval by regulatory authorities of two new TB drugs, 
bedaquiline and delamanid9; and the expanding TB vaccine pipeline.10   
However progress towards achieving WHO global TB control targets in appears to have slowed 
down over the past 2 years. The 2014 annual WHO Report1 shows reversal in previous downward 
trends of estimated global TB case load. Half a million more cases of TB globally in 2013 than 
previously estimated brought the total number of TB cases to 9 million. Alarmingly, each year, 3 
million people with TB are still being ‘missed’ by health systems and approximately 1.5 million 
people die from TB. MDR-TB and extensively drug-resistant TB (XDR-TB) continue to spread 
relentlessly in Eastern Europe, Asia and Africa, with an estimated 480,000 new MDR-TB cases in 
2013 alone.1 The actual case load of drug-susceptible and drug-resistant TB may be higher than 
current estimates as indicated by national surveys11 and autopsy studies.12-14 These are due to 
programmatic weaknesses of laboratory and diagnostic infrastructures, case detection, recording 
and reporting systems. Furthermore, lack of resources coupled with other operational challenges 
contribute to the low cure rates for MDR-TB15-17 despite the use of TB drug treatment regimens 
recommended by WHO.1   
Further disappointment came from the long awaited results of the flouroquinolone trials18-20 which 
failed to demonstrate any usefulness of moxifloxacin or ofloxacin in reducing the duration of TB 
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therapy from six to four months. The TB new drug and vaccines developmental pipeline remains 
slim.21 Despite two decades of investment into development of new diagnostics, drugs, treatment 
regimens and vaccines,22,23 we are still faced with a global TB emergency. This worrying status quo 
indicates that prevailing approaches to preventing, diagnosing, treating and managing TB requires 
critical appraisal by scientists, healthcare workers, funders, advocacy groups and governments. The 
time has now come for a radical re-think to effect a game change in facilitating progress towards 
achieving improved treatment outcomes and for achieving aims of the WHO end TB strategy.24 
Ever since the declaration of TB as a global emergency in 1993 by the WHO, a major focus has been 
on developing new drugs, diagnostics and vaccines which target Mycobacterium tuberculosis (M.tb) 
- the microorganism central to pathogenesis of TB. For over two decades, funders, pharmaceutical 
companies, scientists, advocates and policy makers have focused on eradication of M.tb via 
antibiotic therapy, a  concept that M.tb is the main cause of the ongoing global TB pandemic. This 
thinking is in line with Louis Pasteur's (1822-1895) ‘Germ Theory of disease causation,’ which 
gained widespread acceptance starting in the mid-19th century.25 This focus continues till today 
despite the fact that there are two billion people in the world infected with M.tb who do not 
develop active TB disease,26 and that the dramatic decline of TB in much of Europe and North 
America in the first half of the 20th century occurred well before the discovery of anti-TB drugs.27-30  
In contrast to Pasteur’s theory, Pierre Jacques Antoine Béchamp (1816-1908) proposed an 
alternate theory of disease causation - a host–pathogen relationship that  promoted the concept 
that it was not the microorganism that caused disease, but it was the human body’s ‘internal 
milieu’ or ‘terrain’ that was critical to development of disease after infection by the 
microorganism.25  Claude Bernard, a renowned physiologist from the same era, tried for years to 
convince Pasteur of the importance and validity of Bechamp's theory but failed to do so.  Prior to 
his death, Pasteur finally acknowledged the ‘terrain’ theory saying, “Béchamp avait raison, le 
microbe n'est rien. Le terrain est tout.” (“Bechamp was right- The microbe is nothing. The terrain is 
everything”). 16  It is well known that a wide range of ‘host factors’ alter the human body’s ‘internal 
milieu’ (terrain) and are responsible for increased susceptibility to developing active TB disease, 
poor treatment response and for increased mortality from TB.27-30 These include: immune-
dysregulation from any cause (including stress, poor living conditions, socio-economic factors, 
micronutrient deficiencies, HIV), malnutrition, aberrant or excess host inflammatory response to 
infection, alcohol and substance abuse, co-morbidities with non-communicable diseases such as 
diabetes, smoking and chronic obstructive airways disease, pneumoconiosis, all of which are 
important drivers of the global TB pandemic.   
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An important component of the WHO post-2015 global End TB strategy24 is ‘research’. It is now 
important that in addition to the current investments into development of new diagnostics, drugs, 
biomarkers and vaccines, a major investment is made into research on development of therapies 
which target a range of “host factors” involved in TB immuno-pathogenesis, increased susceptibility 
to developing TB disease, and development of excess inflammatory responses which result in tissue 
damage and end organ dysfunction. Host-directed therapies (HDTs)31-36 constitute a diverse range 
of immunological, biological and drug interventions which modulate anti-M.tb protective innate 
and adaptive immunity, reduce excess inflammation, repair or prevent tissue damage or enhance 
the effectiveness of TB drug therapy by modulating host factors. The use of HDTs as adjunct to 
standard anti-TB therapy could also reduce the duration of therapy, and result in improved 
treatment outcomes for drug sensitive and drug resistant TB, and may decrease relapse rates.   
A wide range of HDTs 31-36 targeting the ‘host terrain’ are now being investigated for use as adjunct 
to current TB drug treatment regimens. These include: ‘repurposing’ commonly used drugs for 
diabetes, epilepsy, peptic ulcers, hypercholesterolemia, asthma, cancer and arthritis which have 
shown promise in vitro and in animal models; immunomodulatory agents, use of Vitamin D and 
phenyl butyrate, heat killed environmental mycobacteria; and ‘cellular therapy’ using the patient’s 
own bone marrow derived stromal cells.  Selected list of HDTs under evaluation or ready for 
evaluation in clinical trials are listed in Table 1. These need serious consideration by scientists, 
pharma, governments and the global community. 
All these have potential to alter the ‘host terrain’ in favour of the host, and will require 
development and further evaluation in randomized controlled clinical trials. Importantly, the 
uptake of any research findings into policy and their effective translation into programmatic 
implementation into health services needs to be innovatively addressed through more meaningful 
engagement of scientists, healthcare workers and end users (patients and governments) in high TB 
burden countries. A persisting bugbear of current basic science and clinical trials research being 
conducted in low resourced, high TB endemic countries is that much of frontline research is 
dominated and driven by researchers from high income, developed country institutions without full 
and equitable engagement of those from developing countries.37-40 This discrepancy needs to be 
seriously addressed and redressed through mechanisms which will ensure equitable and fair 
partnerships and must now be a priority for all funding agencies and research consortia.  
Several recent developments provide further hope for taking forward evaluation of adjunct HDTs in 
randomized clinical trials and improving current status quo of TB treatment and control efforts. The 
formation of the Host-Directed Therapies Network (HDT-NET)41 consortium, which held their 
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inaugural symposium in Cape Town, South Africa on April 7, 2015 hosted by the South African 
Medical Research Council.  Our network is all inclusive and open to any interested group, and will 
be extended to include Eastern Europe, Asia and South American country partners. Currently it 
comprises partners from 19 African and 11 European countries. HDT-NET aims to evaluate through 
randomized controlled clinical trials (RCTs) a range of adjunct HDTs for potentially: (a) Shortening 
the duration of treatment for drug-susceptible TB (DS-TB) multi-/extensively-drug resistant TB 
(MDR-/XDR-TB); (b) Improving treatment outcomes (mortality/morbidity) for MDR-/XDR-TB 
patients; and for specific clinical conditions associated with tissue injury such as HIV co-infected 
individuals with DS-TB and MDR/XDR-TB, miliary TB and TB meningitis; (c) Preventing recurrence of 
TB; (d)  Improving treatment outcome of TB- and/or HIV- positive individuals with co-morbidities, 
such as NCDs (e.g. diabetes) and any cancers. This will create a more holistic approach for high 
quality care and to regain the upper hand in the fight against TB.  
Critically, this initiative is committed to developing and maintaining high quality clinical trials and 
laboratory infrastructure at all partner sites irrespective of current capabilities. This will include 
staffing, infrastructure, facilities for cell culture, immunology, mycobacteriology and drug 
sensitivity testing, diagnostics, data entry/storage, protocol harmonization, communication, 
biobanking, end user involvement, ethics, continuing professional development, and networking 
with other trials consortia. Central to its ethos is twinning of research closely to capacity 
development and training with an aim to develop and nurture high caliber cadre of African and 
other developing country researchers (scientists, health and laboratory personnel), who will be 
suitably empowered to take active independent leadership of high quality, locally relevant 
research. A range of postdoctoral fellows, PhDs, Masters, Diploma students will be mentored in 
close alignment with the design, development and conduct of clinical trials. The Africa-Europe HDT-
NET consortium will allow for access to a broader range of multidisciplinary expertise for research, 
training and supervision, and will enable broader knowledge and resource acquisition to support 
trials of other poverty-related diseases to be hosted in each country.  
Several funder initiatives also provide hope for trialing HDTs and aligning research with capacity 
development and training: 1) The German Ministry for Science and Education to fund five Research 
Networks for Health Innovations under African Leadership with 8 million Euros per year;42 2) The 
National Institutes of Health, USA partners with high TB burden country governments to co-fund 
Regional Prospective Observational Research for Tuberculosis (RePORT)43 and 3). The European and 
Developing Countries Clinical Trials Partnership (EDCTP2) launched formally in Cape Town in 
December, 2014.44 There are unique opportunities for tackling the TB epidemic through 
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development of equitable north-south clinical trials research and training partnerships.45,46 Other 
funders such as the Wellcome Trust,47 the UK Medical Research Council,48 NIH Fogarty49 and other 
initiatives are also aligning to build developing country-led development of internationally 
competitive researchers. Since a large range of HDTs require to be evaluated in randomized clinical 
trials over the next decade, the time is now ripe for these funders to harness and pool resources for 
better coordination of national and regional research programs and to reduce fragmentation and 
duplication and achieve optimal deliverables.   
All these funder initiatives can only succeed if close engagement of developing country scientists, 
healthcare workers, patient groups, governments and policy makers in order to facilitate timely 
translation of research findings into policy and practice and for trained scientists to secure better 
careers. We are of the firm belief that it is only through empowerment of the younger generation 
scientific and healthcare leaders of the future to conduct the best quality science and to think more 
collaboratively beyond individual agendas, that the current status quo can be changed significantly. 
The conduct of a numerous clinical trials using a whole range of HDTs trial will allow for basic 
science studies to be conducted on biological samples obtained from a large cohort of patients 
from wide geographical areas so that the specific mechanisms of action of HDTs, their value in TB 
management can be defined.  Understanding the specific mechanisms by which these drugs act 
and the relationship of these mechanisms to M.tb pathogenesis will be important in selecting 
appropriate adjunct host-directed therapy.   Investments into newer scientific research should be 
aligned with parallel international efforts at improving social and living conditions through policy 
and adequate social protection programmes which address health inequalities more generally. 
Only then will significant progress be made in achieving WHO post-2015 End TB strategy goals, and 
gains in achieving TB control will be enhanced and sustained.    
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Table 1: Host-directed therapies (compiled from references 31-36) 
HDT  TARGETED EFFECT AND HDT 
GROUPINGS 
GENERIC PRODUCT GROUP EXAMPLES OF 
POTENTIAL HDT 
MODE OF ACTION 
    
Repurposing commonly used 
drugs for reduction of excess or 
tissue damaging inflammation  
Non-steroidal anti-
inflammatory drugs^ 
(Analgesics and arthritis) 
Ibuprofen Inhibits prostaglandin production via cyclooxygenase (COX) 
inhibition. Reduces lung pathology,tissue inflammation and            
M. tb burden in  mouse models. 
and/or  for modulation of  innate 
and adaptive immune responses 
Biguanides^ 
(Diabetes drugs) 
 Metformin 
  
Inhibits inhibits mitochondrial glycerophosphate 
dehydrogenase. Inhibits M. tuberculosis growth by enhancing 
macrophage autophagy by promoting phagolysosome fusion 
and increasing mitochondrial ROS production. In mice infected 
with M. tb, metformin improves pulmonary pathology and 
reduces bacterial load. 
 Tetracycline* 
(Antibacterial antibiotic) 
 Doxycycline Matrix metalloproteinase inhibitor which prevents degradation 
of collagen and other structural proteins in lung tissue 
 Statins* 
(Cholesteroal lowering 
drugs)  
 Simvastatin 
 Rosuvastatin 
Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
and agonists of peroxisome proliferator activated receptor-γ.  
Statins reduce the formation of lipid droplets by mycobacteria 
and reduce survival of M. tb in macrophages by inducing 
autophagy and maturation of the phagosome 
 Phosphodiesterase 
inhibitors* (Vascular and 
Anti-inflammatory agents ) 
Sildenafil (Viagra) 
Cilostazol (Pletal) 
Modulation of host cyclic nucleotide phosphodiesterase (PDE). 
In mice cilostazol plus sildenafil accelerates the clearance of 
M.tb bacilli from the lungs.    
  
 
Protein kinase inhibitors* 
(Used for chronic 
myelogenous leukemia) 
Imatinib (Gleevec) 
 
Direct pharmacological effect on macrophage function, 
promoting acidification and maturation of phagosomes. In 
mouse models reduces intracellular M. tb survival in vitro. Also 
increases neutrophil and monocyte numbers contributing to 
anti-M.tb host immune response 
Cellular therapy for reduction of 
excess or tissue damaging 
inflammation  and modulation of 
immune responses 
Bone-marrow derived 
stromal cells^ 
Patient’s own 
bone marrow 
derived stromal 
cells (MSCs) 
MSCs produce prostaglandin E2 (PGE2) that decreases 
unproductive inflammation by limiting excess of type I – 
interferon production and decreased M.tb proliferation. They 
could modulate deleterious inflammation and  may have tissue-
repairing effects. Phase 2 trial underway. 
Heat killed environmental 
saprophytic mycobacteria for 
modulation of immune responses 
Environmental 
mycobacteria^ 
M.vaccae,                    
M. indicus pranii 
(M.w), and               
M. manresensis   
Heat killed environmental mycobacteria induce regulatory T 
lymphocytes and promote macrophage effects.  M.vaccae 
enhances Th1 and switch off the Th2 response. Being evaluated 
for both treatment and prevention of TB. 
^ under evaluation  *ready for evaluation 
